Cytek Biosciences (CTKB) Shares Outstanding (2020 - 2026)

Cytek Biosciences (CTKB) has 7 years of Shares Outstanding (Entity) data on file, last reported at $129.1 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 1.21% year-over-year to $129.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $129.1 million (up 1.21% YoY) and the FY2025 annual result came in at $128.6 million, down 0.51% from the prior year.
• Shares Outstanding (Entity) held at $129.1 million in Q1 2026, from $128.6 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $136.3 million in Q2 2023 to a low of $127.2 million in Q2 2025.
• A 5-year average of $131.7 million and a median of $131.3 million in 2024 frame the typical range for Shares Outstanding (Entity).
• Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) jumped 322.47% — and 2024, when it slipped 4.26%.
• Tracing CTKB's Shares Outstanding (Entity) over 5 years: stood at $135.4 million in 2022, then slipped by 3.44% to $130.7 million in 2023, then decreased by 1.15% to $129.2 million in 2024, then fell by 0.51% to $128.6 million in 2025, then increased by 0.46% to $129.1 million in 2026.
• The last three Shares Outstanding (Entity) figures came in at $129.1 million (Q1 2026), $128.6 million (Q4 2025), and $127.9 million (Q3 2025), per Business Quant data.